Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature

1. Tohen

M

Jacobs

TG

Feldman

PD

2000

Onset of action of antipsychotics in the treatment of

mania.

Bipolar Disord

2

261

268

2. Wolfsperger

M

Greil

W

Rossler

W

Grohmann

R

2007

Pharmacological treatment of acute mania in psychiatric

in-patients between 1994 and 2004.

J Affect Disord

99

9

17

3. Healy

D

2006

The latest mania: selling bipolar disorder.

PLoS Med

3

e185

doi:10.1371/journal.pmed.0030185

4. Malhi

GS

Adams

D

Berk

M

2009

Medicating mood with maintenance in mind: bipolar depression

pharmacotherapy.

Bipolar Disord

11

Suppl 2

55

76

5. Spielmans

GI

Parry

PI

2010

From evidence-based medicine to marketing-based medicine:

evidence from internal industry documents.

J Bioeth Inquiry

7

13

29

6. Healy

D

2010

From mania to bipolar disorder.

Yatham

LN

Maj

M

Bipolar disorder: clinical and neurobiological foundations

Oxford

John Wiley & Sons, Ltd

1

7

7. Mark

TL

2010

For what diagnoses are psychotropic medications being

prescribed?: a nationally representative survey of

physicians.

CNS Drugs

24

319

326

8. Depp

C

Ojeda

VD

Mastin

W

Unutzer

J

Gilmer

TP

2008

Trends in use of antipsychotics and mood stabilizers among

Medicaid beneficiaries with bipolar disorder, 2001-2004.

Psychiatr Serv

59

1169

1174

9. Frank

E

Prien

RF

Jarrett

RB

Keller

MB

Kupfer

DJ

1991

Conceptualization and rationale for consensus definitions of

terms in major depressive disorder. Remission, recovery, relapse, and

recurrence.

Arch Gen Psychiatry

48

851

855

10. Storosum

JG

van Zwieten

BJ

Vermeulen

HD

Wohlfarth

T

van den Brink

W

2001

Relapse and recurrence prevention in major depression: a critical

review of placebo-controlled efficacy studies with special emphasis on

methodological issues.

Eur Psychiatry

16

327

335

11. Ghaemi

SN

Pardo

TB

Hsu

DJ

2004

Strategies for preventing the recurrence of bipolar

disorder.

J Clin Psychiatry

65

Suppl 10

16

23

12. Goodwin

FK

Whitham

EA

Ghaemi

SN

2011

Relapse prevention in bipolar disorder: have any neuroleptics

been shown to be ‘mood stabilizers’?

CNS Drugs

In press

13. Sachs

GS

1996

Bipolar mood disorder: practical strategies for acute and

maintenance phase treatment.

J Clin Psychopharmacol

16

32S

47S

14. Sachs

GS

Printz

DJ

Kahn

DA

Carpenter

D

Docherty

JP

2000

The expert consensus guideline series: medication treatment of

bipolar disorder 2000.

Postgrad Med Spec No

1

104

15. Suppes

T

Dennehy

EB

Hirschfeld

RM

Altshuler

LL

Bowden

CL

2005

The Texas implementation of medication algorithms: update to the

algorithms for treatment of bipolar I disorder.

J Clin Psychiatry

66

870

886

16. Perlis

RH

Welge

JA

Vornik

LA

Hirschfeld

RM

Keck PE Jr.

2006

Atypical antipsychotics in the treatment of mania: a

meta-analysis of randomized, placebo-controlled trials.

J Clin Psychiatry

67

509

516

17. Scherk

H

Pajonk

FG

Leucht

S

2007

Second-generation antipsychotic agents in the treatment of acute

mania: a systematic review and meta-analysis of randomized controlled

trials.

Arch Gen Psychiatry

64

442

455

18. Vieta

E

Sanchez-Moreno

J

2008

Acute and long-term treatment of mania.

Dialogues Clin Neurosci

10

165

179

19. Bauer

MS

Mitchner

L

2004

What is a “mood stabilizer”? An evidence-based

response.

Am J Psychiatry

161

3

18

20. Ghaemi

SN

2001

On defining ‘mood stabilizer’.

Bipolar Disord

3

154

158

21. Goodwin

FK

Jamison

KR

2007

Manic-depressive illness: bipolar disorders and recurrent

depression.

New York

Oxford University Press

22. Suppes

T

Vieta

E

Liu

S

Brecher

M

Paulsson

B

2009

Maintenance treatment for patients with bipolar I disorder:

results from a north american study of quetiapine in combination with

lithium or divalproex (trial 127).

Am J Psychiatry

166

476

488

23. Geddes

JR

Goodwin

GM

Rendell

J

Azorin

JM

Cipriani

A

2010

Lithium plus valproate combination therapy versus monotherapy for

relapse prevention in bipolar I disorder (BALANCE): a randomised open-label

trial.

Lancet

375

385

395

24. Ghaemi

SN

Hsu

DJ

Thase

ME

Wisniewski

SR

Nierenberg

AA

2006

Pharmacological treatment patterns at study entry for the first

500 STEP-BD participants.

Psychiatr Serv

57

660

665

25. Lim

PZ

Tunis

SL

Edell

WS

Jensik

SE

Tohen

M

2001

Medication prescribing patterns for patients with bipolar I

disorder in hospital settings: adherence to published practice

guidelines.

Bipolar Disord

3

165

173

26. Frangou

S

Raymont

V

Bettany

D

2002

The Maudsley bipolar disorder project. A survey of psychotropic

prescribing patterns in bipolar I disorder.

Bipolar Disord

4

378

385

27. Blanco

C

Laje

G

Olfson

M

Marcus

SC

Pincus

HA

2002

Trends in the treatment of bipolar disorder by outpatient

psychiatrists.

Am J Psychiatry

159

1005

1010

28. Tohen

M

Baraibar

G

Kando

JC

Mirin

J

Zarate CA Jr.

1995

Prescribing trends of antidepressants in bipolar

depression.

J Clin Psychiatry

56

260

264

29. U.S. Food and Drug Administration

2005

Approval package for 21-436/S-005 & S-008 &

21-713/S-003.

Rockville (Maryland)

U.S. Food and Drug Administration

30. IMS Health

2010

Top 15 U.S. pharmaceutical products by sales. IMS National Sales

Perspectives(TM).

Norwalk

IMS Health

31. Chow

ST

von Loesecke

A

Hohenberg

KW

Epstein

M

Buurma

AK

2008

Brands and strategies: atypical antipsychotics.

Waltham (Massachusetts)

Decision Resources, Inc

32. Diak

I

Mehta

H

2008

New Molecular Entity review follow-up:

aripiprazole.

Rockville (Maryland)

U.S. Food and Drug Administration

33. Cuttler

L

Silvers

JB

Singh

J

Tsai

AC

Radcliffe

D

2005

Physician decisions to discontinue long-term medications using a

two-stage framework: the case of growth hormone therapy.

Med Care

43

1185

1193

34. Levit

K

Smith

C

Cowan

C

Lazenby

H

Sensenig

A

2003

Trends in U.S. health care spending, 2001.

Health Aff (Millwood)

22

154

164

35. Bristol-Myers Squibb Company

2010

Clinical trials registry.

New York

Bristol Myers Squibb Co

36. Gidiere

S

2006

The federal information manual.

Chicago

American Bar Association

37. Moynihan

R

Bero

L

Ross-Degnan

D

Henry

D

Lee

K

2000

Coverage by the news media of the benefits and risks of

medications.

N Engl J Med

342

1645

1650

38. Fleiss

J

1981

Statistical methods for rates and proportions. 2nd

edition.

New York

Wiley

39. Keck

PE

Jr

Calabrese

JR

McQuade

RD

Carson

WH

Carlson

BX

2006

A randomized, double-blind, placebo-controlled 26-week trial of

aripiprazole in recently manic patients with bipolar I

disorder.

J Clin Psychiatry

67

626

637

40. Keck

PE

Jr

Calabrese

JR

McIntyre

RS

McQuade

RD

Carson

WH

2007

Aripiprazole monotherapy for maintenance therapy in bipolar I

disorder: a 100-week, double-blind study versus placebo.

J Clin Psychiatry

68

1480

1491

41. Otsuka Pharmaceutical Co., Ltd.

2010

A multicenter, placebo-controlled, double-blind investigative

extension trial of the safety and efficacy of aripiprazole in the treatment

of patients with bipolar disorder experiencing a manic or mixed episode

(NCT00606177).

Tokyo

Otsuka Pharmaceutical Co., Ltd

42. Bristol-Myers Squibb Company

2008

A multicenter, randomized, double-blind, placebo-controlled study

of aripiprazole monotherapy in the treatment of acutely manic patients with

bipolar I disorder (CN138-135LT).

New York

Bristol-Myers Squibb Co

43. Keck

PE

Orsulak

PJ

Cutler

AJ

Sanchez

R

Torbeyns

A

2009

Aripiprazole monotherapy in the treatment of acute bipolar I

mania: a randomized, double-blind, placebo- and lithium-controlled

study.

J Affect Disord

112

36

49

44. Muzina

DJ

Momah

C

Eudicone

JM

Pikalov

A

McQuade

RD

2008

Aripiprazole monotherapy in patients with rapid-cycling bipolar I

disorder: an analysis from a long-term, double-blind, placebo-controlled

study.

Int J Clin Pract

62

679

687

45. Keck

PE

Jr

Marcus

R

Tourkodimitris

S

Ali

M

Liebeskind

A

2003

A placebo-controlled, double-blind study of the efficacy and

safety of aripiprazole in patients with acute bipolar mania.

Am J Psychiatry

160

1651

1658

46. He

K

2004

Statistical review and evaluation. Center for Drug Evaluation and

Research approval package for 21-436/S-005 & S-008 &

21-713/S-003.

Rockville (Maryland)

U.S. Food and Drug Administration

47. Bowden

CL

Calabrese

JR

Sachs

G

Yatham

LN

Asghar

SA

2003

A placebo-controlled 18-month trial of lamotrigine and lithium

maintenance treatment in recently manic or hypomanic patients with bipolar I

disorder.

Arch Gen Psychiatry

60

392

400

48. Tohen

M

Calabrese

JR

Sachs

GS

Banov

MD

Detke

HC

2006

Randomized, placebo-controlled trial of olanzapine as maintenance

therapy in patients with bipolar I disorder responding to acute treatment

with olanzapine.

Am J Psychiatry

163

247

256

49. Calabrese

JR

Bowden

CL

Sachs

G

Yatham

LN

Behnke

K

2003

A placebo-controlled 18-month trial of lamotrigine and lithium

maintenance treatment in recently depressed patients with bipolar I

disorder.

J Clin Psychiatry

64

1013

1024

50. Angst

J

Sellaro

R

2000

Historical perspectives and natural history of bipolar

disorder.

Biol Psychiatry

48

445

457

51. Tohen

M

Frank

E

Bowden

CL

Colom

F

Ghaemi

SN

2009

The International Society for Bipolar Disorders (ISBD) Task Force

report on the nomenclature of course and outcome in bipolar

disorders.

Bipolar Disord

11

453

473

52. Ghaemi

SN

2010

From BALANCE to DSM-5: taking lithium seriously.

Bipolar Disord

12

673

677

53. Quitkin

FM

Rabkin

JG

1981

Methodological problems in studies of depressive disorder:

utility of the discontinuation design.

J Clin Psychopharmacol

1

283

288

54. Quitkin

F

Rifkin

A

Klein

DF

1976

Prophylaxis of affective disorders. Current status of

knowledge.

Arch Gen Psychiatry

33

337

341

55. Prodruchny

TA

2004

Clinical review. Center for Drug Evaluation and Research approval

package for 21-436/S-005 & S-008 & 21-713/S-003.

Rockville (Maryland)

U.S. Food and Drug Administration

56. Ghaemi

SN

2006

Hippocratic psychopharmacology for bipolar disorder: an

expert's opinion.

Psychiatry (Edgmont)

3

30

39

57. Deshauer

D

Fergusson

D

Duffy

A

Albuquerque

J

Grof

P

2005

Re-evaluation of randomized control trials of lithium

monotherapy: a cohort effect.

Bipolar Disord

7

382

387

58. Smith

LA

Cornelius

V

Warnock

A

Bell

A

Young

AH

2007

Effectiveness of mood stabilizers and antipsychotics in the

maintenance phase of bipolar disorder: a systematic review of randomized

controlled trials.

Bipolar Disord

9

394

412

59. Greenhouse

JB

Stangl

D

Kupfer

DJ

Prien

RF

1991

Methodologic issues in maintenance therapy clinical

trials.

Arch Gen Psychiatry

48

313

318

60. Wehr

TA

1990

Unnecessary confusion about opposite findings in two studies of

tricyclic treatment of bipolar illness.

Arch Gen Psychiatry

47

787

788

61. Sachs

GS

Thase

ME

2000

Bipolar disorder therapeutics: maintenance

treatment.

Biol Psychiatry

48

573

581

62. Shapiro

DR

Quitkin

FM

Fleiss

JL

1990

Unnecessary confusion about opposite findings in two studies of

tricyclic treatment of bipolar illness. Reply.

Arch Gen Psychiatry

47

788

63. Deshauer

D

Moher

D

Fergusson

D

Moher

E

Sampson

M

2008

Selective serotonin reuptake inhibitors for unipolar depression:

a systematic review of classic long-term randomized controlled

trials.

CMAJ

178

1293

1301

64. Levenson

M

2008

Antiepileptic drugs and suicidality.

Rockville (Maryland)

U.S. Food and Drug Administration

65. Stone

M

Laughren

T

Jones

ML

Levenson

M

Holland

PC

2009

Risk of suicidality in clinical trials of antidepressants in

adults: analysis of proprietary data submitted to US Food and Drug

Administration.

BMJ

339

b2880

66. Calabrese

JR

Rapport

DJ

Shelton

MD

Kimmel

SE

2001

Evolving methodologies in bipolar disorder maintenance

research.

Br J Psychiatry

Suppl 41

s157

163

67. Calabrese

JR

Rapport

DJ

1999

Mood stabilizers and the evolution of maintenance study designs

in bipolar I disorder.

J Clin Psychiatry

60

Suppl 5

5

13; discussion 14-15

68. Lapierre

YD

Gagnon

A

Kokkinidis

L

1980

Rapid recurrence of mania following lithium

withdrawal.

Biol Psychiatry

15

859

864

69. Mander

AJ

Loudon

JB

1988

Rapid recurrence of mania following abrupt discontinuation of

lithium.

Lancet

2

15

17

70. Baldessarini

RJ

Suppes

T

Tondo

L

1996

Lithium withdrawal in bipolar disorder: implications for clinical

practice and experimental therapeutics research.

Am J Ther

3

492

496

71. Suppes

T

Baldessarini

RJ

Faedda

GL

Tondo

L

Tohen

M

1993

Discontinuation of maintenance treatment in bipolar disorder:

risks and implications.

Harv Rev Psychiatry

1

131

144

72. Faedda

GL

Tondo

L

Baldessarini

RJ

Suppes

T

Tohen

M

1993

Outcome after rapid vs gradual discontinuation of lithium

treatment in bipolar disorders.

Arch Gen Psychiatry

50

448

455

73. Baldessarini

RJ

1995

Risks and implications of interrupting maintenance psychotropic

drug therapy.

Psychother Psychosom

63

137

141

74. Baldessarini

RJ

Tondo

L

Faedda

GL

Suppes

TR

Floris

G

1996

Effects of the rate of discontinuing lithium maintenance

treatment in bipolar disorders.

J Clin Psychiatry

57

441

448

75. Baldessarini

RJ

Tondo

L

Ghiani

C

Lepri

B

2010

Illness risk following rapid versus gradual discontinuation of

antidepressants.

Am J Psychiatry

167

934

941

76. Suppes

T

Baldessarini

RJ

Faedda

GL

Tohen

M

1991

Risk of recurrence following discontinuation of lithium treatment

in bipolar disorder.

Arch Gen Psychiatry

48

1082

1088

77. Goodwin

GM

1994

Recurrence of mania after lithium withdrawal. Implications for

the use of lithium in the treatment of bipolar affective

disorder.

Br J Psychiatry

164

149

152

78. Franks

MA

Macritchie

KA

Mahmood

T

Young

AH

2008

Bouncing back: is the bipolar rebound phenomenon peculiar to

lithium? A retrospective naturalistic study.

J Psychopharmacol

22

452

456

79. Viguera

AC

Baldessarini

RJ

Hegarty

JD

van Kammen

DP

Tohen

M

1997

Clinical risk following abrupt and gradual withdrawal of

maintenance neuroleptic treatment.

Arch Gen Psychiatry

54

49

55

80. Baldessarini

RJ

Viguera

AC

1998

Medication removal and research in psychotic

disorders.

Arch Gen Psychiatry

55

281

283

81. Healy

D

2010

Treatment-induced stress syndromes.

Med Hypotheses

74

764

768

82. Geddes

JR

Burgess

S

Hawton

K

Jamison

K

Goodwin

GM

2004

Long-term lithium therapy for bipolar disorder: systematic review

and meta-analysis of randomized controlled trials.

Am J Psychiatry

161

217

222

83. Bowden

CL

Calabrese

JR

McElroy

SL

Gyulai

L

Wassef

A

2000

A randomized, placebo-controlled 12-month trial of divalproex and

lithium in treatment of outpatients with bipolar I disorder. Divalproex

Maintenance Study Group.

Arch Gen Psychiatry

57

481

489

84. Bowden

CL

Swann

AC

Calabrese

JR

McElroy

SL

Morris

D

1997

Maintenance clinical trials in bipolar disorder: design

implications of the divalproex-lithium-placebo study.

Psychopharmacol Bull

33

693

699

85. Coppen

A

Noguera

R

Bailey

J

Burns

BH

Swani

MS

1971

Prophylactic lithium in affective disorders. Controlled

trial.

Lancet

2

275

279

86. Prien

RF

Caffey EMJr., Klett CJ

1973

Prophylactic efficacy of lithium carbonate in manic-depressive

illness. Report of the Veterans Administration and National Institute of

Mental Health collaborative study group.

Arch Gen Psychiatry

28

337

341

87. Kemp

DE

Canan

F

Goldstein

BI

McIntyre

RS

2009

Long-acting risperidone: a review of its role in the treatment of

bipolar disorder.

Adv Ther

26

588

599

88. Fountoulakis

KN

Vieta

E

2009

Efficacy and safety of aripiprazole in the treatment of bipolar

disorder: a systematic review.

Ann Gen Psychiatry

8

16

89. Muzina

DJ

2009

Treatment and prevention of mania in bipolar I disorder: focus on

aripiprazole.

Neuropsychiatr Dis Treat

5

279

288

90. McIntyre

RS

Woldeyohannes

HO

Yasgur

BS

Soczynska

JK

Miranda

A

2007

Maintenance treatment in bipolar disorder: a focus on

aripiprazole.

Expert Rev Neurother

7

919

925

91. McIntyre

RS

Soczynska

JK

Woldeyohannes

HO

Miranda

A

Konarski

JZ

2007

Aripiprazole: pharmacology and evidence in bipolar

disorder.

Expert Opin Pharmacother

8

1001

1009

92. McIntyre

RS

2010

Aripiprazole for the maintenance treatment of bipolar I disorder:

a review.

Clin Ther

32

Suppl 1

S32

38

93. Garcia-Amador

M

Pacchiarotti

I

Valenti

M

Sanchez

RF

Goikolea

JM

2006

Role of aripiprazole in treating mood disorders.

Expert Rev Neurother

6

1777

1783

94. Fagiolini

A

2008

Practical guidance for prescribing with aripiprazole in bipolar

disorder.

Curr Med Res Opin

24

2691

2702

95. Ulusahin

A

2008

Ikiuclu bozuklukta aripiprazol [Aripiprazole for the

treatment of bipolar disorder].

Klinik Psikofarmakoloji Bulteni [Bulletin of Clinical

Psychopharmacology]

18

S27

S34

96. Yatham

LN

Kennedy

SH

Schaffer

A

Parikh

SV

Beaulieu

S

2009

Canadian Network for Mood and Anxiety Treatments (CANMAT) and

International Society for Bipolar Disorders (ISBD) collaborative update of

CANMAT guidelines for the management of patients with bipolar disorder:

update 2009.

Bipolar Disord

11

225

255

97. Goodwin

GM

2009

Evidence-based guidelines for treating bipolar disorder: revised

second edition—recommendations from the British Association for

Psychopharmacology.

J Psychopharmacol

23

346

388

98. Forbes

A

Findling

RL

Nyilas

M

Forbes

RA

Aurang

C

2008

Long-term efficacy of aripiprazole in pediatric patients with

bipolar I disorder.

New Research Abstracts; May 3-8 American Psychiatric

Association

297

99. Baldessarini

RJ

Tohen

M

Tondo

L

2000

Maintenance treatment in bipolar disorder.

Arch Gen Psychiatry

57

490

492

100. Goodwin

GM

Malhi

GS

2007

What is a mood stabilizer?

Psychol Med

37

609

614

101. Bowden

CL

Calabrese

JR

Wallin

BA

Swann

AC

McElroy

SL

1995

Illness characteristics of patients in clinical drug studies of

mania.

Psychopharmacol Bull

31

103

109

102. Post

RM

Keck

P

Jr

Rush

AJ

2002

New designs for studies of the prophylaxis of bipolar

disorder.

J Clin Psychopharmacol

22

1

3

103. Prien

RF

Kupfer

DJ

1989

Outside analysis of a multicenter collaborative

study.

Arch Gen Psychiatry

46

462

464

104. Tohen

M

Lin

D

2006

Maintenance treatment in bipolar disorder.

Psychiatry (Edgmont)

3

43

45

105. Swann

AC

2006

Treating bipolar disorder: for the patient or against the

illness?

Psychiatry (Edgmont)

3

40

42

106. Mallinckrodt

C

Chuang-Stein